Trimethoprim is a specific inhibitor of dihydrofolate reductase. When added to amino acid supplemented cultures of Escherichia coli, protein, ribonucleic acid (RNA), and deoxyribonucleic acid synthesis are rapidly inhibited. It is shown that thymidylate and purine synthesis must continuously occur if the inhibition is to be maintained. These results are interpreted as demonstrating that in vivo...

We have studied antifolate-resistant rodent cell lines with respect to dihydrofolate reductase gene expression and expression of the "classic" multidrug resistance phenotype by flow cytometry. Using a series of antifolate-resistant and colchicine-resistant Chinese hamster ovary cell lines obtained by single-step and stepwise selection protocols, we show that viable cell staining with fluorescei...

background: the present study was formulated in order to determine pol­ymorphism of dihydropteroate synthetase gene (dhps) of plasmodium vivax (p . vivax ) in hormozgan province, southern iran and mutations at codons 382, 383, 512, 553, and 585 associated with resistance of p. vivax to sulfadoxine. method : one-hundred eighteen isolates of p. vivax were prepared within 2007-2008 to determine di...

The trimethoprim-resistant dihydrofolate reductase associated with the R plasmid R388 was isolated from strains that over-produce the enzyme. It was purified to apparent homogeneity by affinity chromatography and two consecutive gel filtration steps under native and denaturing conditions. The purified enzyme is composed of four identical subunits with molecular weights of 8300. A 1100 bp long D...

Halobacterium volcanii mutants that are resistant to the dihydrofolate reductase inhibitor trimethoprim contain DNA sequence amplifications. This paper describes the cloning and nucleic acid sequencing of the amplified DNA sequence of the H. volcanii mutant WR215. This sequence contains an open reading frame that codes for an amino acid sequence that is homologous to the amino acid sequences of...

Roswell Park Memorial Institute 4265 human lymphoblasts were grown with three dihydrofolate reductase inhibitors: a 2,4-diaminopteridine, methotrexate; a 2,4-diaminoquinazoline, chlorasquin; and, a 2,4-diaminotriazine, triazinate. In the absence of inhibitor, dihydrofolate reductase activity increased to a peak at mid-log growth and then declined during the later growth stages. When cells were ...